NEWSROOM

Medical Research

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Jul 7, 2025

Meeting adjourned to Monday, July 21, 2025 at 9:30 a.m. Mountain Time Broomfield, CO, July 7, 2025 - PRISM MediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for July 7, 2025 has...

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

Jun 25, 2025

The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Company reaffirms internal interim results of CLARITY...

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum

Jun 24, 2025

Dr. Kris Radcliff to Highlight MR Spectroscopy and Augmented Intelligence (AI)-Based Platform at State of Spine Surgery Think Tank BROOMFIELD, Colo., June 24, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the upcoming State of...

BioStem Technologies Completes Enrollment in Clinical Trial Evaluating BioREtain® Amnion Chorion for Treatment of Diabetic Foot Ulcers

BioStem Technologies Completes Enrollment in Clinical Trial Evaluating BioREtain® Amnion Chorion for Treatment of Diabetic Foot Ulcers

Jun 23, 2025

Head-to-head study comparing BioREtain®- processed Amnion Chorion (BR-AC) allograft to standard of care initiated in Q4 2024 to demonstrate healing superiority Topline results and full data analysis expected in Q4 2025 POMPANO BEACH, Fla., June 23, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today...

BioStem Technologies Completes Enrollment in Clinical Trial Evaluating BioREtain® Amnion Chorion for Treatment of Diabetic Foot Ulcers

Ernst & Young LLP (EY US) Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award Winner

Jun 17, 2025

Award celebrates bold leaders shaping the future through the world’s most ground-breaking companies POMPANO BEACH, Fla., June 17, 2025 - PRISM MediaWire - Ernst & Young LLP (EY US) announced that Jason Matuszewski, CEO and Chairman of the Board of BioStem Technologies (OTC: BSEM), was named an Entrepreneur Of The Year 2025 Florida Award winner. Entrepreneur Of The Year is the preeminent competitive awards program for entrepreneurs and leaders of high-growth companies. For 40 years, EY US...

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site

Jun 10, 2025

UHealth — University of Miami Health System and the University of Miami Miller School of Medicine provide world-class research and renowned clinical expertise in spine surgery CLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., June 10,...

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

Jun 4, 2025

Supports late-stage development and scalable manufacturing for LP-310, a non-steroidal oral rinse therapy for Oral Lichen Planus, a condition with no approved treatments PITTSBURGH, June 4, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced that it has re-signed its manufacturing collaboration agreement with Cook...

BioStem Technologies Provides Update on the Company’s Form 10 Submission and SEC Review Process

BioStem Technologies Provides Update on the Company’s Form 10 Submission and SEC Review Process

Jun 3, 2025

Upon SEC approval of the amended Form 10, BioStem expects to advance its uplisting to Nasdaq POMPANO BEACH, Fla., June 3, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today provides an update on the Company’s Form 10 registration statement and SEC review process. BioStem believes it has favorably...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 29, 2025

POMPANO BEACH, Fla., May 29, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami. Jason Matuszewski, the Company’s CEO, will participate in a fireside chat and will be available for...

Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates

Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates

May 28, 2025

Issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease JACKSON CENTER, Pa., May 28, 2025 - PRISM MediaWire - Halberd Corporation (OTC: HALB) in cooperation with Athena Telemedicine Partners, LLC, announces astounding clinical efficacy for our patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney...

Catheter Precision, Inc. Receives CE Mark for LockeT

Catheter Precision, Inc. Receives CE Mark for LockeT

May 27, 2025

Opens Multi-Billion Market Opportunity for the Company First Order for 100 Units Received FORT MILL, S.C., May 27, 2025 - PRISM MediaWire - Catheter Precision, Inc. (NYSE American: VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that it has received CE Mark approval for LockeT, the latest advanced vascular closure device. Receipt of the CE Mark indicates compliance with European Union (EU)...

BioStem Technologies Provides Update on the Company’s Form 10 Submission and SEC Review Process

Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award finalist

May 22, 2025

Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future POMPANO BEACH, Fla., May 22, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (the “Company” or “BioStem”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, CEO of BioStem is an Ernst & Young LLP (EY US) finalist for the prestigious Entrepreneur...

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

May 20, 2025

USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologies CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 20, 2025 - PRISM MediaWire - Aclarion, Inc.,...

American Shared Hospital Services Announces First Quarter Financial Results Conference Call

American Shared Hospital Services Announces First Quarter Financial Results Conference Call

May 12, 2025

Call Scheduled for May 15th at 12:00 PM ET SAN FRANCISCO, May 12, 2025 - PRISM MediaWire - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through its leasing and direct patient care services segments, today announced that the Company will hold a conference call to discuss its first quarter 2025 financial results on May 15th at 12:00 pm ET. The first...

PRISM MarketView Honors Mental Health Awareness Month with a Spotlight on Emerging Innovators

PRISM MarketView Honors Mental Health Awareness Month with a Spotlight on Emerging Innovators

May 12, 2025

NEW YORK, May 12, 2025 - PRISM MediaWire - In recognition of Mental Health Awareness Month, PRISM MarketView reaffirms its commitment to highlighting the critical importance of mental health and the ongoing efforts to improve mental well-being across the nation. Established in 1949 by Mental Health America, Mental Health Awareness Month serves to educate the public about mental illnesses, promote mental wellness, and reduce the stigma associated with mental health conditions. This year's...

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

May 7, 2025

IRVINE, Calif., May 7, 2025 - PRISM MediaWire - Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. Registration for the live webinar, which will discuss financial results and include Q&A, is required at the following link: Oncocyte Q1...

Aclarion Welcomes Advocate Health as CLARITY Trial Site

Aclarion Welcomes Advocate Health as CLARITY Trial Site

May 5, 2025

Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Press Audio: BROOMFIELD, Colo., May 05, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON,...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies to Host First Quarter 2025 Financial Results Conference Call on May 12, 2025

Apr 30, 2025

Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., April 30, 2025 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces it will release its first quarter 2025 financial results on Monday, May 12, 2025, and will host a conference call and webcast at 4:30 PM ET. The webcast will feature an overview of the...

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

Apr 23, 2025

Joint meeting to be held in Las Vegas, May 14-17 Presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute Topline study results demonstrate clinically meaningful improvements in OLP Visible lesion resolution during treatment; return toward baseline post-dosing supports localized activity Listen: PITTSBURGH, April 23, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company...

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Apr 22, 2025

Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward Phase 2b IND Submission and Broader Regulatory Engagement Listen: PITTSBURGH, April 22, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies to Present at the Centri Capital Conference

Apr 21, 2025

The presentation will be webcast at 10:30 AM ET on April 22, 2025 POMPANO BEACH, Fla., April 21, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, is pleased to announce that its Chief Executive Officer, Jason Matuszewski, will be presenting and holding one-on-one meetings at the upcoming Centri Capital...

PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath

PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath

Apr 15, 2025

Feature Details Company Milestones and 2025 Catalysts Across Gene Therapy and Ophthalmic Programs NEW YORK, April 15, 2025 - PRISM MediaWire - PRISM MarketView today published a Q&A feature with Dr. George Magrath, Chief Executive Officer of Opus Genetics, Inc. (“Opus Genetics” or the “Company”) (Nasdaq: IRD), a clinical-stage gene therapy company developing treatments for inherited retinal diseases (IRDs) and broader ophthalmic conditions. Dr. George Magrath, Chief Executive Officer of...

American Shared Hospital Services Announces First Quarter Financial Results Conference Call

American Shared Hospital Services to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub

Apr 9, 2025

Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025 SAN FRANCISCO, April 09, 2025 - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through its leasing or direct patient care services segments, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23,...

American Shared Hospital Services Announces First Quarter Financial Results Conference Call

American Shared Hospital Services Reports Fourth Quarter and Strong Full Year 2024 Financial Results

Apr 4, 2025

Appoints Gary Delanois as Chief Executive Officer Conference Call Scheduled for 1:00 PM ET Today SAN FRANCISCO, CA, April 4, 2025 - PRISM MediaWire - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through its leasing or direct patient care services segments, today announced financial results for the fourth quarter and full year ended December 31, 2024. Key...

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025

IRVINE, Calif., April 2, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025. In addition, CEO Josh Riggs will participate in a fireside chat at the conference. During the event, Josh and Andrea will discuss Oncocyte’s innovative diagnostic technologies...

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California

Apr 2, 2025

MICSC are leaders in Los Angeles providing MRI and Diagnostic Imaging services MICSC expands access to Nociscan beyond Beverly Hills now available in Santa Monica Broomfield, CO, April 2, 2025 - PRISM MediaWire - Aclarion, Inc.,(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its Nociscan...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies Announces Extension to File 2024 Annual Report with OTC

Apr 1, 2025

POMPANO BEACH, Fla., April 1, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces it has filed for an extension to submit its annual report for the year ended December 31, 2024 to the OTC The company is currently undergoing a mandatory Securities Exchange Commission (SEC) review process related to its Form 10 registration...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Announces Notice of Allowance for Two U.S. Patent Applications

Mar 31, 2025

Company continues to innovate and strengthen its patent portfolio with 43 issued patents and 26 pending for its advanced wound care technology POMPANO BEACH, Fla., March 31, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of...

SS Innovations Continues its International Growth, Receiving Medical Device Regulatory Approvals for the SSi Mantra 3 Surgical Robotic System in both the Philippines and Ukraine

SS Innovations Continues its International Growth, Receiving Medical Device Regulatory Approvals for the SSi Mantra 3 Surgical Robotic System in both the Philippines and Ukraine

Mar 28, 2025

Fort Lauderdale, Fla. March 28, 2025 - PRISM MediaWire - SS Innovations International, Inc. (OTC: SSII) (“SS Innovations” or the “Company”), a developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable for and accessible to a global population, has received regulatory approvals for its SSi Mantra 3 Surgical Robotic System in both the Philippines and Ukraine. SS Innovations International along with RBGM Medical Express Sales Inc., its Manila...

SS Innovations Continues its International Growth, Receiving Medical Device Regulatory Approvals for the SSi Mantra 3 Surgical Robotic System in both the Philippines and Ukraine

SS Innovations International, Inc. Achieves Another Milestone by Successfully Performing Over 2,000 km North-to-South Robotic Cardiac Telesurgery with its SSi Mantra 3 Surgical Robotic System

Mar 27, 2025

The SSI Mantra 3 Surgical Robotic System enabled a seamless connection from SS Innovations headquarters in Gurugram, India to Aster CMI Hospital in Bengaluru, India covering a distance over 2,000 km. The SSi Mantra, India’s first CDSCO*-approved surgical robotic system for telesurgery, brings precision and accessibility to complex surgical procedures. Fort Lauderdale, FL, March 27, 2025 - PRISM MediaWire - SS Innovations International, Inc. (OTC: SSII) (“SS...